-
Flexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
-
Flexion Therapeutics (FLXN): Non Deal Roadshow Thoughts - BMO
-
Flexion Therapeutics (FLXN) Prices 4.8M Shares at $25.50
-
Flexion Therapeutics Announces Pricing of Public Offering of Common Stock
-
Flexion Therapeutics (FLXN) Announces 4M Share Common Offering
-
Flexion Therapeutics Announces Proposed Public Offering of Common Stock
-
Flexion Therapeutics (FLXN) PT Raised to $37 at BMO Capital; 'Getting Lead Product Through is Monumental Milestone'
-
BMO Capital Positive on Flexion Therapeutics (FLXN) Despite No FDA Priority Review for Zilretta NDA
-
Flexion Therapeutics (FLXN) Hit Important Milestone with Zilretta NDA - BMO Capital
-
Flexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
-
Flexion Therapeutics (FLXN) Prices 3.6M Share Offering at $18/Sh
-
Flexion Therapeutics Announces Pricing of Public Offering of Common Stock
-
Flexion Therapeutics (FLXN) Announces Common Stock Offering
-
Flexion Therapeutics Announces Proposed Public Offering of Common Stock
-
BMO Capital Starts Flexion Therapeutics (FLXN) at Outperform
-
Flexion Therapeutics (FLXN) Prices 5.5M Common Stock Offering at $14
-
Flexion Therapeutics Announces Pricing of Public Offering of Common Stock
-
Flexion Therapeutics (FLXN) Commences $60M Offering of Common Stock
-
Flexion Therapeutics Announces Proposed Public Offering of Common Stock
-
Flexion Therapeutics (FLXN) Prices Larger 5.04M Common Offering at $17/Share
-
Flexion Therapeutics (FLXN) Announces 3.5M Common Offering
-
BMO Capital Starts Flexion Therapeutics (FLXN) at Outperform
-
Flexion Therapeutics (FLXN) IPO Ramps 20% Higher
-
Flexion Therapeutics (FLXN) Files $86.25M IPO